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Lymphomas are a diverse group of malignant disorders that
include non-Hodgkin’s lymphoma and Hodgkin lymphoma.
Collectively, lymphomas represent the fifth most common cancer
type and the fifth leading cause of cancer death in the US. In 2006,
the American Cancer Society estimates that more than 66000
individuals in the US will be diagnosed with lymphoma, the
majority of which (88%) will be classified as non-Hodgkin’s
lymphoma. Although enormous progress in cancer biology has
been made over the past few decades, resulting in an overall
decrease in the frequency of most cancers, the incidence of
lymphomas continues to increase unabated. Clearly, an urgent
need exists for newer and more effective treatments for these
diseases. Far too many years have been spent combining existing
cytotoxic drugs with only limited success.
In general terms, current cancer treatment strategies are tending
to move away from nonspecific cytotoxic agents to biologically
targeted drugs with more specific mechanisms of antitumour
action. This approach is especially true for the management of
non-Hodgkin’s lymphoma, whose cancer cells can be targeted with
greater reliability. One such group of targeted chemotherapeutic
agents is the histone deacetylase (HDAC) inhibitors, which
promote gene transcription by decreasing binding of histones to
DNA and thereby produce growth arrest and apoptosis in cancer
cells. Histone deacetylases have been implicated in the pathogen-
esis of lymphomas via regulation of the BCL-6 gene and, thus, their
inhibition may provide a unique target for antilymphoma therapy.
One promising new weapon in our armamentarium to treat
patients with lymphomas is the HDAC inhibitor vorinostat
(suberoylanilide hydroxamic acid or SAHA). This supplement
highlights our current understanding of the antitumour effects of
vorinostat and reviews our clinical experience to date on the use of
vorinostat in treating advanced haematological malignancies,
including Hodgkin’s disease and select subtypes of non-Hodgkin’s
lymphoma. The three articles comprising this supplement are
based on individual presentations by eminent investigators at a
symposium held in conjunction with the 9th International
Conference on Malignant Lymphoma in Lugano, Switzerland, on
7 June 2005. Dr Victoria Richon presents a wealth of experimental
data delineating the biological basis for the antitumour activity of
vorinostat. Her comprehensive review indicates that vorinostat
produces potent antiproliferative effects on a wide variety
of transformed cells through the accumulation of acetylated
proteins, including the core nucleosomal histones and other
proteins. However, the therapeutic benefit of HDAC inhibitors
may well extend beyond simple chromatin remodelling and
may also involve effects on the acetylation of essential transcrip-
tion factors such as BCL-6. Dr Owen O‘Connor discusses the initial
clinical experience with vorinostat, demonstrating potent antitu-
mour efficacy and a favourable tolerability profile of oral and
intravenous formulations in a variety of haematological malignan-
cies. Finally, Dr Madeleine Duvic provides exciting new clinical data
showing the benefits of vorinostat therapy in treating advanced,
heavily pretreated malignant cutaneous T-cell lymphoma patients.
Collectively, these presentations provide encouraging data on
the potential clinical efficacy of vorinostat as a single therapeutic
modality in treating patients with lymphomas. Such data as are
presented in this volume have led, in part, to the recent approval of
this agent by the US Food and Drug Administration for the
treatment of patients with relapsed or refractory CTCL. Undoubt-
edly, however, the greatest benefit from this agent will be as part of
multidrug regimens. The rational combination of vorinostat with
agents that have complementary mechanisms of antitumour action
may ultimately lead to optimisation of chemotherapy regimens
for lymphoma patients and perhaps lead to a reduction in our
dependence on the more toxic, nonspecific cytotoxic agents.
Combination therapies incorporating vorinostat are likely to
contribute greatly to our increased ability to cure patients with
lymphomas and may herald a new era in cancer therapy.
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